Pneumocystis carinii pneumonia in AIDS. New concepts for an old problem;Neumonia for pneumocystis cariniien pacientes con sida nuevos concertos para un viejo problema

Medicina

Volumn 59, Issue 2, 1999, Pages 187-194

  Bottaro, Edgardo ^a,b  

^a Hospital Santojanni Buenos Aires   (Argentina)

^b NONE   (Argentina)

Author keywords

AIDS; Antiretroviral therapy; Dihydropteroate synthase; Pneumocystis carinii; Prophylaxis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AIDS RELATED COMPLEX; HUMAN; PATHOPHYSIOLOGY; PNEUMOCYSTIS PNEUMONIA; REVIEW; RISK FACTOR;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; HUMANS; PNEUMONIA, PNEUMOCYSTIS; RISK FACTORS;

EID: 0032619531     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Chagas C. Nova tripanozomiaze humana. Mem Inst Oswaldo Crur, 1909:1660-5.
2. th edition, New York: Churchill Livingstone. 1995.
3. Ng VL, Yajko DM, Hadley WK. Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997; 401-18.
4. Stringer JR, Walzer PD. Molecular biology and epidemiology of Pneumocystis carinii infection in AIDS. AIDS 1996;10:561-71.
5. th edition, Philadelphia: Saunders 1997. pp 275-300.
6. Mazars E, Guyot K, Durand I, Dei-Gas E, Boucher S, Ben Abderrazak S, et al. Isoenzyme diversity in Pneumocystis carinii horn rats, mice, and rabbits. J Infect Dis 1997; 175: 655-60.
7. Meuwissen JH, Tauber 1, Leeuwenberg AD, Beckers PJ, Sieben M. Parasitologic and sérologie observations of infection with Pneumocystis in humans. J Infect Dis 1977; 136:43-9.
8. Edman JC. Molecular Biology: future effects on taxonomy, diagnosis, and therapy. Pp 822-4. In Masur H, moderator. Pneumocystis pneumonia: from bench to clinic. Ann Intern Med 1989; 111:813-26.
9. Pixley FJ, Wakefield AE, Banerji S, Hopkin JM. Mitochondria! gene sequences show fungal homology for Pneumocystis carinii. Mol Microbiol 1991; 5: 1347-51.
10. Meade JC, Stringer JR. Cloning and characterization of an ATPase gene from Pneumocystis carinii which closely resembles fungal H ATPases. J Eukaryot Microbiol 1995; 42: 298-307.
11. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ, Sogin ML. Ribosomal RNA sequence shows Pneumocystis cariniHo be a member of the fungi. Nature 1988; 334: 519-22.
12. Jacobs JL, Libby DM, Winters RA, Gelmont DM, Fried ED, Hartman BJ, et al. A cluster of Pneumocystis carinii pneumonia in adults without predisposing illness. N Engl J Med 1991; 324: 246-50.
13. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992; 267: 832-7.
14. Dabar GR, Duncan RA. Opportunistic Infections & CD4lymphocytopenia in chronic lymphocytic leukemia treated with fludarabine. IDSA 35m Annual Meeting, Moscone Center, San Francisco, September 1997.
15. Smith DK, Neal JJ, Holmberg SD. Unexplained opportunistic infections and CD4+ lymphocytopenia without HIV infections. N Engl J Med 1993; 328: 373-9.
16. Watanabe JM, Chinchinian H, Weitz C, Mcllvaine SK. Pneumocystis carinii pneumonia in a family. JAMA 1965; 71:156-9.
17. Palange P, Serra P, Di Sabato F, Contini C, Giacovazzo M. Pneumocystis carinii pneumonia in a patient with chronic obstructive pulmonary disease but not evident immunoincompetence. Clin Infect Dis 1994; 19: 543-4.
18. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981 ; 305: 1425-31.
19. Masur H, Michelis MA, Greene JB, Onorato J, Stouwe RA, Holzman RS, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981; 305: 1431-8.
20. Chusid MJ, Heyrman KA. An outbreak of Pneumocystis carinii pneumonia at a pédiatrie hospital. Pediatrics 1978; 62:1031-5.
21. Lane HC. Immunologie bases for susceptibility. In: Masur H, moderator. Pneumocystis pneumonia: from bench to clinic. Ann Intern Med 1989; 111: 813-26.
22. Vargas SL, Hughes WT, Wakefield AE, Oz HS. Limited persistence in and subsequent elimination of Pnemocystis carinii from the lungs after P. carinii pneumonia. J Infect Dis 1995; 172:506-10.
23. Chen W, Gigliotti F, Harmsen AG. Latency is not an inevitable outcome of infection with Pneumocystis carinii. Infect Immun 1993; 61: 5406-9.
24. Hennequin C, Page B, Roux P, Legendre C, Kreis H. Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit. Eur J Clin Microbiol Infect Dis 1995; 14: 122-6.
25. Peters SE, Wakefield AE, Sinclair K, Millard PR, Hopkin JM. A search for Pneumocystis carinii in post-mortem lungs by DNA amplification. J Pathol 1992; 166: 195-8.
26. Keely SP, Stringer JR . Sequences of Pneumocystis carinii f. sp. hominis strains associated with recurrent pneumonia vary at multiple loci. J Clin Microbiol 1997, 35: 2745-7.
27. Keely SP, Stringer JR, Baughman RP, Linke MJ, Walzer PD, Smulian G. Genetic Variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J Infect Dis 1995; 172: 595-8.
28. Leigh TR, Mille MJ, Jameson B, Collins JV. Serum titres of Pneumocystis carinii antibody in health care workers caring for patients with AIDS. Thorax 1993; 48: 619-21.
29. Frenkel JK, Good JT, Shultz JA. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab Invest 1966; 15; 1559-77.
30. Walzer PD, Powell RD Jr, Yoneda K. Experimental Pneumocystis carinii pneumonia in different strains of cortisonized mice. Inf Immuni 1979; 24: 939-47.
31. th Conference on Rètrovirus and Opportunistic Infections. Washington DC, January 1997.
32. Bartlett MS, Vermund SH, Durant PJ, Shaw MM, Smith JW, Tang JJ, et al. Detection of Pneumocystis carinii DNA air samples: likely enviromental risk to susceptible persons. J Clin Microbiol 1997; 35: 2511-3.
33. Wakefield AE. DNA sequences identical to Pneumocystis carinii f. sp. carinii and Pneumocystis carinii f. sp. in samples of air spora. J Clin Microbiol 1996; 34: 1754-9.
34. Olsson M, Lidman C, Latouche S, Björman A, Roux P, Linder E, et al. Identification of Pneumocystis cariniif. sp. hominis gene sequences in filtered air in hospital environments. J Clin Microbiol 1998; 36:1737-40.
35. Hughes WT. Natural mode of acquisition for de novo infection with Pneumocystis carinii. J Infect Dis 1982; 145: 842-6.
36. Vogel P, Miller CJ, Lowenstine LL, Lackner AA. Evidence of horizontal transmission of Pneumocystis carinii pneumonia in simian immunodeficiency virus-infected rhesus macaques. J Infect Dis 1993; 168: 836-43.
37. Cere N, Polack B, Chanteloup NK, Coudert P. Natural transmission of Pneumocystis carinii in nonimmunosuppressed animals: early contagiousness of experimentally infected rabbits (Oryctolagus cuniculus). J Clin Microbiol 1997; 35: 2670-2.
38. Viner BL. Pneumocystis Pneumonia. In: Libman H, Witzburg RA. HIV Infection. Boston: Little Brown 1995.
39. th Annual Meeting, Denver, November 1998.
40. CDC. 1997 USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. MMWR 1997; 46: RR-12.
41. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agent C/?emoffter1998; 42: 995-1004.
42. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Marath C, et al. Randomised placebo-controlled trial of Ritonavir in advanced HIV-1 disease. LanceM998; 351-543-9.
43. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus Indinavir in persons with human immunodeficiency virus infection and CD4 counts of 200 per millimeter or less. N Engl J Med 1997, 337: 725-33.
44. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDSdefining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997; 11: F101-5.
45. th Conference on Retrovirus and Opportunistic Infections, Chicago, February 1998.
46. Murphy R, El-Sadr W, Cheng T, Luski Hawk R, Yurik T, Neaton J, et al. Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 034/ACTG 277 Study. 55h Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
47. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
48. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
49. Hotzer CD, Jacobson MA, Hadley WK, Huang L, Stanley HD, Montant! R, et al. Decline in specific opportunistic infections (Ol) at San Francisco General Hospital (SFGH). 5'h Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
50. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
51. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
52. CDC. Update: Trends in AIDS incidence-United States, 1996. MMWR 1997; 46: 861-7.
53. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
54. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engt J Med 1998; 338: 853-60.
55. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
56. Ferrando S, van Gorp W, McElhiney M, Goggin K, Sewell M, Rabkin J. Highly active antiretroviral treatment in HIV infection: benefits for neuropshychological function. AIDS 1998;12:F65-70.
57. Carr A, Marriott D, Field A, Vasak E, Cooper DA. Treatment of HIV-1 associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. LanceM 998; 351: 256-61.
58. Hicks CB, Myers SA, Giner J. Resolution of intractable molluscum contagiosus in a human immunodeficiency virus-infected patient after institution of antiretroviral therapy with Ritonavir. Clin Infect Dis 1997; 24:1023-5.
59. Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL. Regression of AIDS-related Kaposi's sarcoma following treatment with an HIV-1 protease inhibitor AIDS 1997; 11: 261-2.
60. Whitcup SM, Fortin E, Nussenblatt RB, Polis MA, Muccioli C, Beifort R. Therapeutic effect of combination antiretroviral therapy on Cytomegalovirus retinitis (letter). JAMA 1997; 277:1519-20.
61. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine D. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12: 1459-64.
62. Ministerio de Salud y Acciön Social. Programa Nacional de Lucha contra los Retrovirus del Humano y SIDA. Boletfn sobre el SIDA en la Republica Argentina. Marzo 1998.
63. th Conference on Retrovirus and Opportunistes Infections. Chicago, February 1998.
64. Fleury S, de Boer RJ, Rizzardi GP, Wolthers KG, Otto SA, Welbon CC, et al. Limited CD4 T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med 1998, 4: 794-801.
65. Powderly WG, Landay A, Lederman MM. Recovery of the immune system with antiretroviral therapy. The end of opportunism? JAMA 1998; 280: 72-7.
66. Connors M, Kovacs JA, Krevat S, Gea-Banacloche JC, Sneller MC, Flanigan M, et al. HIV infection induces changes in CD4 T-cell phenotype and depletions within the CD4 T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997; 3: 533-40.
67. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
68. Hicks CB, Markert L, Ottinger J, Ferrari G, Harmon L, Demarest J, et al. Immunologie changes in blood and lymph nodes induced by highly active antiretroviral therapy (HAART). 5'h Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
69. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
70. Gorochov G, Neumann AU, Kereveur A, Parizot C, Taisheng L, Katlama C, et al. Disordering of CD4 and CDS T-cell repertoires during progression to AIDS and restoration or the CD4 repertoire under antiviral therapy. &h Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
71. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
72. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
73. Sleasman J, Goodenow SM, Nelson R, Wilfert D, Hutson A, Heath-Chiozzi M, et al. Reconstitution of memory (Cd45RO) and naive (CD45RA) CD4 T-cell following ritonavir therapy in HIV-infected children with advanced disease. 5'h Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
74. Hengel RL, Jones BM, Kennedy SM, Hubbard MS, McDougal JS. Activation and function markers of CD4 and CDS T cells after potent anti-HIV-1 therapy. 5m Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
75. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
76. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351: 1682-6.
77. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
78. Masur H. Prevention and treatment of Pneumocystis pneumonia. N Eng! J Med 1992; 327: 1853-60.
79. th Annual Meeting, Moscone Center. San Francisco, September 1997.
80. Phillips AN, Eron JJ, Bartlett JA, Rubin M, Johnson J, Price S, et al. HIV-1 RNA levels and the development of clinical disease. AIDS 1996; 10: 859-65.
81. Lyles RH, Chu C, Margolick J, Detels R, Giorgi J, AI-Hboul Q, et al. HIV RNA and CD4 lymphocyte count relate differently to the occurrence of PCP, CMV, and MAC disease. 5m Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
82. Ravaux I, Chadapavd S, Quinson AN, Dahan V, Gallais H. Discontinue primary prophylaxis regimens in selected HIV-infected patients treated with HAART. 12'h World AIDS Conference, Geneva July 1998.
83. Garcfa Vazquez E, Marrero Frances J, Garcfa Delgado R, Mainez C, Gorgolas M, Fernändez Gerrero ML. Withdrawal of Pneumocystis carinii pneumonia (PCP) prophylaxis after HAART in patients with AIDS. 12 World AIDS Conference, Geneva July 1998.
84. Furrer H, Opravil M, Bernasconi E, Anwar D, Battegay M, Frank A, et al. Is it safe to stop primary PCP prophylaxis in patients treated with antiretroviral combination regimens? 12111 World AIDS Conference, Geneva July 1998.
85. Hughes WT. Pneumocystis carinii pneumonitis. IDCP 1997:6:379-84.
86. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259:1185-9.
87. CDC. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR1992; 41:1-11.
88. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994; 120: 932-44.
89. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
90. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
91. th Conference on Retroviruses and opportunistic infections. Washington DC, January 1997.
92. th Conference on Retroviruses and opportunistic infections. Washington, DC, January 1997.
93. Mei Q, Gurunathan S, Masur H, Kovacs JA. Failure of co-trimoxazole in Pneumocystis carinii infection and mutations in dihydropteroate synthasa gene. Lancet 1998; 351:1631-2.
94. Saah A, Hoover DR, Yun Peng MS, Phair JP, Visscher B, Kingsiey LA, et al. Failure of Pneumocystis prophylaxis. Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. JAMA 1995; 273:1197-202.'
95. th World AIDS Conference, Geneva July 1998.
96. th Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998.
97. loannidis JPA, Cappelleri JC, Skolnik PR, Lau J, Sacks HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996, 156:177-88.
98. th World AIDS Conference, Geneva July 1998.
99. Kazanjian P, Locke AB, Hossler PA, Lane BR, Bartlert MS, Smith JW, et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 1998; 12: 873-8.